{"product_id":"anti-cd19-car-negative-control-nfat-luciferase-reporter-jurkat-cell-line-cd19-scfv-cd28-transmembrane-motif-bhc18200222","title":"Anti-CD19 CAR negative control\/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif)","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table tr:nth-child(even) th{background:#dce8fb}\n.bhp-desc .bhp-spec-table tr:nth-child(even) td{background:#f0f6ff}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600;margin-bottom:10px}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-license-box{background:#f5f5f5;border:1px solid #ddd;border-radius:4px;padding:12px 16px;font-size:14px;color:#444;margin:10px 0 14px}\n.bhp-desc .bhp-regulatory-row{display:flex;gap:16px;flex-wrap:wrap;margin:6px 0 10px}\n.bhp-desc .bhp-reg-item{background:#f0f6ff;border:1px solid #ccd9f0;border-radius:4px;padding:6px 12px;font-size:14px}\n.bhp-desc .bhp-reg-item strong{color:#003366;display:block;font-size:12px;text-transform:uppercase;letter-spacing:.5px}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eThe development of CAR-T cells is a complex process that requires multiple steps in the workflow including I) screening and sequencing of mAbs that are specific to the cancer antigens; II) engineering and validation of scFv and scFv-CAR of different varieties for their specificities and activities; III) production of high titer lentivirus for CAR constructs; IV) isolation, activation and expansion of primary T cells from healthy donors or patients that exhibit a specific cellular phenotype; V) transduction of activated T cells with CAR-encoding lentivirus; VI) validation of engineered CAR-T cells through FACS and functional analysis. BPS Bioscience has developed a series of CAR-T products, including lentiviruses, reporter cell lines and fully validated functional CAR-T cells for a variety of targets such as CD19 and BCMA. In this product, anti-CD19 CAR negative control and NFAT-luciferase reporter are co-transfected into a Jurkat cell line, where the anti-CD19 scFv binds to CD19, however, it does not induce the activation of CAR and luciferase reporter through NFAT as the intracellular activation motifs are missing. Anti-CD19 scFv linked to the CD28 transmembrane region was cloned into a lentivector, and packaged using a safe, replication incompetent, and VSV-G pseudotyped lentiviral packaging system, in which the gene of anti-CD19 CAR negative control is driven by an EF-1α promotor. Anti-CD19 CAR negative control Jurkat\/NFAT reporter cell line was generated by the transduction of anti-CD19 CAR negative control lentivirus into an NFAT-luciferase reporter Jurkat cell line. In these cells, the luciferase reporter should not be activated upon co-culture with CD19\/CHO target cells (BPS Bioscience #79561). Anti-CD19 CAR\/NFAT-luciferase reporter Jurkat cell line (BPS Bioscience, #79853) is a great system for primary screening of anti-CD19 CAR and predicting its mechanism of action before testing on patient-derived primary T cells. The same anti-CD19 CAR lentivirus (BPS Bioscience, #79851) was also used to transduce primary T cells to make primary anti-CD19 CAR-T cells, which showed IFN-γ production and cytotoxic killing of CD19+ tumor cells in co-culture experiments, indicating that there is a good correlation between the reporter activity in CAR reporter Jurkat cell line and functional activation of primary CAR-T cells when co-cultured with target cells.\u003c\/p\u003e\n\u003ch2\u003eProduct Description\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eCAR-T\u003c\/span\u003e\n\u003cp\u003eAnti-CD19 CAR negative control\/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR negative control and NFAT-luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without any intracellular signaling domains. The reporter cell line has been validated for anti- CD19 expression by FACS, while the stimulation by target cells including CD19\/CHO recombinant cell line has not activated the luciferase reporter gene in this cell line. The cell line can be used for the negative control of anti-CD19 CAR\/Jurkat-NFAT cell line (BPS Bioscience, #79853).\u003c\/p\u003e\n\u003ch2\u003eProduct Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eHost Cell Line\u003c\/th\u003e\n\u003ctd\u003eJurkat (clone E6-1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost Species\u003c\/th\u003e\n\u003ctd\u003eHuman t lymphoblast, suspension\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTransfection Method\u003c\/th\u003e\n\u003ctd\u003eLentivirus, no catalog number,\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplied As\u003c\/th\u003e\n\u003ctd\u003eEach vial contains 2 x 10^6 cells in 1 ml of 10% DMSO and 90% FBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHarmonized Tariff Code\u003c\/th\u003e\n\u003ctd\u003e3002-5900\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eQuality Control \u0026amp; Validation\u003c\/h2\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✓ Mycoplasma-Tested\u003c\/span\u003e\n\u003cp\u003eThe cell line has been screened using Lonza MycoAlert Mycoplasma Detection kit (Lonza, #LT07-318) to confirm the absence of Mycoplasma species.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cp style=\"margin:0 0 4px\"\u003e⚠ Avoid freeze\/thaw cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch2\u003eRegulatory Information\u003c\/h2\u003e\n\u003cdiv class=\"bhp-regulatory-row\"\u003e\n\u003cdiv class=\"bhp-reg-item\"\u003e\n\u003cstrong\u003eLicense Required\u003c\/strong\u003eYes\u003c\/div\u003e\n\u003cdiv class=\"bhp-reg-item\"\u003e\n\u003cstrong\u003eLiving Modified Organism\u003c\/strong\u003eYes\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2\u003eLicense Disclosure\u003c\/h2\u003e\n\u003cdiv class=\"bhp-license-box\"\u003ePurchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.\u003c\/div\u003e\n\u003ch2\u003eRelated Products\u003c\/h2\u003e\n\u003cp\u003eRelated Products: Cat. #60690, 60184, 79796, 79784, 79853\u003c\/p\u003e\n\u003cp\u003eRequired Accessories: Cat. #60184,79784,79796,60690\u003c\/p\u003e\n\u003c\/div\u003e","brand":"BPS Bioscience","offers":[{"title":"2 Vials","offer_id":53322322903405,"sku":"79854","price":2465.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/79854_facs.png?v=1778636469","url":"https:\/\/www.ebiohippo.com\/products\/anti-cd19-car-negative-control-nfat-luciferase-reporter-jurkat-cell-line-cd19-scfv-cd28-transmembrane-motif-bhc18200222","provider":"BioHippo","version":"1.0","type":"link"}